WEBULL
WebtradeDownload

Labcorp Holdings (LH) Moved Higher, What Is Driving Attention Now?

Simply Wall St · 3d ago

Labcorp Holdings (LH) drew fresh investor attention after its 2026 Investor Day, where management highlighted an acquisition-driven playbook, reaffirmed multi-year guidance, and spotlighted cancer-focused partnerships and AI-powered diagnostics.

Against that backdrop, Labcorp Holdings has seen momentum build over 2026, with the share price at US$323.97 after a 24.8% 90 day share price return and a 28.7% year to date share price return. The 3 year total shareholder return of 63.9% points to a stronger longer term payoff profile than the 19.4% total shareholder return over the past year.

Extend your research beyond Labcorp Holdings by scanning a curated set of healthcare diagnostics and AI-focused peers in our 39 healthcare AI stocks to identify potential next-wave beneficiaries of the same themes.

After a near 30% year to date surge and a price brushing close to analyst targets, is Labcorp Holdings still priced for more of its AI and acquisition story, or has most of the easy upside already played out before the valuation work even starts?

Most Popular Narrative: 4% Undervalued

Labcorp Holdings is priced only slightly below the most followed fair value estimate of $337.75. The current $323.97 level therefore leaves limited room for error in the underlying story investors are buying into.

The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

See why 6 investors see Labcorp Holdings as 4% undervalued.

Result: Fair Value of $337.75 (UNDERVALUED)

Still, tariffs, regulatory shifts such as PAMA, and pricing pressure in diagnostic contracts could quickly challenge the current Labcorp Holdings upside narrative.

Find out about the key risks to this Labcorp Holdings narrative.

Next Steps

If the mix of upside stories and risk flags around Labcorp Holdings feels finely balanced, act while the information is fresh and test the numbers for yourself. Start by weighing the 3 key rewards and 1 important warning sign.

Looking for more ideas beyond Labcorp Holdings?

Do not stop with a single stock. Broaden your watchlist by testing other angles, spotting patterns, and pressure testing your thesis before your next move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.